PDCD1 and melanoma: Others identified increased frequencies of CX3CR1+ CD8+ T cells in non-small cell lung and melanoma patients who responded to anti-PD-1 therapy, where these cells exhibited migratory capabilities into the tumor site followed by potent tumor rejection (Yamauchi et al., 2021; Yan et al., 2018).